Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Pheonix is developing ADI-PEG-20, a PEGylated arginine deiminase for the potential treatment of hepatocellular carcinoma, for which the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products have granted the drug Orphan Drug status, and melanoma, for which the FDA has also awarded ADI-PEG-20 Orphan Drug status. ADI-PEG-20 is also being investigated for the potential treatment of influenza virus infection and hepatitis C virus infection.
Shen
Li-Jiuan
LJ
School of Pharmacy, College of Medicine, National Taiwan University, 12F 1 Ren-Ai Road, Sec 1, Taipei 100, Taiwan. ljshen@ha.mc.ntu.edu.tw
Shen
Wei-Chiang
WC
D000818:Animals; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D006867:Hydrolases / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D011092:Polyethylene Glycols; D006867:Hydrolases; C512527:ADI PEG20; C019723:arginine deiminase